Deerfield Management Company, L.P. (Series C) Bio Atla, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $615,574 - $1.55 Million	-289,002 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $3.33 Million - $5.43 Million	-175,298 Reduced 37.76%	289,002 $5.67 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $6.44 Million - $9.58 Million	218,919 Added 89.22%	464,300 $13.7 Million
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $1.52 Million - $2.24 Million	39,959 Added 19.45%	245,381 $10.4 Million
Q1 2021 May 17, 2021	SELL	$32.41 - $70.91 $2.43 Million - $5.32 Million	-75,000 Reduced 26.75%	205,422 $10.4 Million
Q4 2020 Feb 16, 2021	BUY	$31.02 - $35.16 $8.7 Million - $9.86 Million	280,422 New	280,422 $9.54 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.3M

Call Options Held

500

Put Options Held

33.5K

Israel Englander Millennium Management LLC | New York, Ny

2.66M
Shares

$4.57 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

2.52M
Shares

$4.33 Million
0.38% of portfolio
Vanguard Group Inc Valley Forge, PA

1.89M
Shares

$3.24 Million
0.0% of portfolio
Morgan Stanley New York, NY

1.86M
Shares

$3.2 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

874K
Shares

$1.5 Million
0.13% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account